Autologous haematopoiesis stem cell transplantation (AHSCT) for treatment-refractory autoimmune diseases in children

被引:1
|
作者
Satirer, Oezlem [1 ,2 ]
Henes, Joerg C. [3 ,4 ]
Doering, Michaela [5 ]
Lesk, Till [6 ]
Benseler, Susanne [7 ,8 ]
Kuemmerle-Deschner, Jasmin Beate [1 ,2 ]
机构
[1] Univ Klinikum Tubingen, Dept Paediat, Tubingen, Baden Wurttembe, Germany
[2] Univ Klinikum Tubingen, Autoinflammat Reference Ctr Tuebingen arcT, Tubingen, Baden Wurttembe, Germany
[3] Univ Klinikum Tubingen, Ctr Interdisciplinary Clin Immunol Rheumatol & Aut, Tubingen, Baden Wurttembe, Germany
[4] Univ Klinikum Tubingen, Dept Internal Med Oncol Haematol Immunol & Rheumat, Tubingen, Baden Wurttembe, Germany
[5] Univ Tubingen, Pediat Hematol & Oncol, Tubingen, Baden Wurttembe, Germany
[6] Univ Klinikum Tubingen, Tubingen, Baden Wurttembe, Germany
[7] Alberta Childrens Hosp Res Inst, Rheumatol, Calgary, AB, Canada
[8] Childrens Hlth Ireland, Dublin, Ireland
来源
RMD OPEN | 2024年 / 10卷 / 03期
关键词
Treatment; Autoimmune Diseases; Hematopoietic Stem Cell Transplantation; JUVENILE IDIOPATHIC ARTHRITIS; CAR T-CELLS; SYSTEMIC-SCLEROSIS; ACTIVITY CRITERIA; INTERNATIONAL CONSENSUS; ETANERCEPT; GUIDELINES; BLOOD; IMMUNOTHERAPY; MULTICENTER;
D O I
10.1136/rmdopen-2024-004381
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To evaluate the long-term effectiveness and safety of autologous haematopoiesis stem cell transplantation (AHSCT) for severe, refractory autoimmune diseases in paediatric patients.Methods A single-centre study of consecutive children and adolescents with refractory autoimmune diseases undergoing AHSCT was performed. Demographics, clinical, laboratory features, pre-AHSCT medications, disease activity and functional status were captured. The primary outcome was progression-free survival, secondary outcomes included overall survival, disease-specific treatment responses, disease activity at the last follow-up and AHSCT safety.Results The study included seven patients: two systemic sclerosis, one pansclerotic morphoea, one eosinophilic fasciitis, one juvenile dermatomyositis and two patients with systemic juvenile idiopathic arthritis; four women, three men median age at AHSCT of 10 years (7-19), median follow-up post-AHSCT of 17 years. Median progression-free survival and overall survival was 4.2 years (95% CI: 0.98 to 8.3) and 17 years (95% CI: 11.8 to 22.1), respectively. Progression-free survival rates at 1 and 2 years post-AHSCT were 100% and 77%, respectively. All children survived. All patients are in clinical remission, only four require ongoing immunotherapy. Safety: Three experienced infections, including HHV6, Candida and Ralstonia sepsis; one developed a systemic inflammatory response syndrome; two new onset secondary autoimmune diseases including autoimmune haemolytic anaemia, Graves' disease and one was found to have a breast fibroadenoma. Treatment toxicity: one cyclophosphamide-associated transient renal failure and pericardial effusion, one patient with amenorrhoea/infertility.Conclusions AHSCT was an effective and safe approach for children and adolescents with treatment-refractory autoimmune diseases. The indication and timing of transplantation requires a careful consideration and a multidisciplinary approach.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 50 条
  • [31] Onset and outcome of pregnancy after autologous haematopoietic stem cell transplantation (AHSCT) for autoimmune diseases: a retrospective study of the EBMT Autoimmune Disease Working Party
    Snarski, E.
    Badoglio, M.
    Moore, J.
    Tan, J.
    Rovira, M.
    Saiz, A.
    Musso, M.
    Martin, T.
    Snowden, J.
    Forge, D.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S377 - S377
  • [32] Autologous Hematopoietic Stem Cell Transplantation (AHSCT): An Evolving Treatment Avenue in Multiple Sclerosis
    Mohammadi, Reihane
    Aryan, Alisam
    Omrani, Mir Davood
    Ghaderian, Sayyed Mohammad Hossein
    Fazeli, Zahra
    BIOLOGICS-TARGETS & THERAPY, 2021, 15 : 53 - 59
  • [33] Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in Advanced, Treatment Refractory Multiple Sclerosis (MS) - a Phase II Clinical Trial
    Massey, Jennifer
    Moore, John
    Sutton, Ian
    Ma, Chun Kei Kris
    Milliken, Sam
    Ma, David
    BLOOD, 2017, 130
  • [34] Multiple autoimmune diseases after autologous stem-cell transplantation
    Bohgaki, Toshiyuki
    Atsumi, Tatsuya
    Koike, Takao
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (26): : 2734 - 2736
  • [35] Complications of autologous hematopoietic stem cell transplantation for patients with autoimmune diseases
    Daikeler, Thomas
    Tichelli, Andre
    Passweg, Jakob
    PEDIATRIC RESEARCH, 2012, 71 (04) : 439 - 444
  • [36] Autologous stem cell transplantation for autoimmune diseases: Issues in protocol development
    McSweeney, PA
    Nash, RA
    Storb, R
    Furst, DE
    Gauthier, J
    Sullivan, KM
    JOURNAL OF RHEUMATOLOGY, 1997, 24 : 79 - 84
  • [37] Autologous haematopoietic stem cell transplantation -: a meaningful therapy in autoimmune diseases?
    Reuss-Borst, M
    Müller, GA
    AKTUELLE RHEUMATOLOGIE, 1999, 24 (03) : 69 - 76
  • [38] Autologous hematopoietic stem cell transplantation for a patient with multiple autoimmune diseases
    Vittayawacharin, Pongthep
    Sy, Michael Y.
    Isfahani, Sanaz Attaripour
    Karnes, William E.
    Kongtim, Piyanuch
    Ciurea, Stefan O.
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (10) : 1659 - 1662
  • [39] Complications of autologous hematopoietic stem cell transplantation for patients with autoimmune diseases
    Thomas Daikeler
    André Tichelli
    Jakob Passweg
    Pediatric Research, 2012, 71 : 439 - 444
  • [40] Successful Treatment of Refractory or Relapsed Hepatoblastoma With Autologous Hematopoietic Stem Cell Transplantation in Children
    Kim, Bo Kyung
    Choi, Jung Yoon
    Hong, Kyung Taek
    Park, Hyun Jin
    Kang, Hyoung Jin
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2024, 46 (05) : e265 - e271